Recombinant human tumor necrosis factor－α receptorⅡ: IgG Fc fusion protein for injection belongs to a etanercept bio-similar, and is a domestically developed generic biological product.
In 2005, Shanghai CPGJ Pharma first attained approval for its injection-purpose recombinant human tumor necrosis factor－α receptorⅡ：IgG Fc fusion protein, with the trade name Etanercept; followed by Shanghai Celgen Bio-Pharmaceutical’s Qiangke; and Zhejiang Hisun Pharma’s product.
Injection-purpose recombinant human tumor necrosis factor－α receptorⅡ: IgG Fc fusion protein in subcutaneous injection applies to moderate and severe active rheumatoid arthritis, adult moderate to severe plaque psoriasis, and active ankylosing spondylitis.
According to data, between 2012 and 2015, injection-purpose recombinant human TNF－α receptorⅡ: IgG Fc fusion protein sales of China’s key city public hospitals grew to 162 million yuan, with medications capping 215 million yuan in 2015, a 7.61% increase over the prior year.
Shanghai CPGJ’s Etanercept accounted for 93.90%, Shanghai Celgen Bio-Pharma’s Qiangke for 5.92%, while Zhejiang Hisun Pharma contributed to 0.17%.
(By our own staff)